Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.47 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11744393 | 0.84 | GABBR2 (0.41) | GABBR2GABBR1LMNAPOLBCYP1A2 | |
| SCHEMBL6174106 | 0.84 | GABBR2 (0.66) | GABBR2GABBR1LMNAPOLBCYP1A2 | |
| SCHEMBL240789 | 0.84 | GABBR2 (0.66) | GABBR2GABBR1LMNAPOLBCYP1A2 | |
| SCHEMBL2484805 | 0.84 | GABBR2 (0.66) | GABBR2GABBR1LMNAPOLBCYP1A2 | |
| SCHEMBL7333184 | 0.84 | HPGD (0.41) | GABBR2GABBR1LMNAPKMNPSR1 | |
| SCHEMBL6722503 | 0.82 | GABBR2 (0.48) | GABBR2GABBR1LMNAPOLBCYP1A2 | |
| SCHEMBL1500385 | 0.82 | GABBR2 (0.48) | GABBR2GABBR1LMNAPOLBCYP1A2 | |
| SCHEMBL11586845 | 0.82 | CES2 (0.57) | GABBR2GABBR1LMNAPOLBMTNR1A | |
| SCHEMBL7324599 | 0.82 | CYP2D6 (0.45) | CYP2D6MEN1KMT2A | |
| SCHEMBL28678413 | 0.81 | GABBR2 (0.44) | GABBR2GABBR1LMNAPOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685248-B1 | OXIDOREDUCTASE FROM METSCHNIKOWIA ZOBELLII | IEP GMBH (DE) | 2010-06-09 | — | — | EP | claimed |
| EP-1383899-B1 | ENZYMATIC METHOD FOR THE ENANTIOSELECTIVE REDUCTION OF KETO COMPOUNDS | IEP GMBH (DE) | 2009-09-23 | — | — | EP | claimed |
| US-20080233619-A1 | Process For the Enantioselective Enzymatic Reduction of Keto Compounds | IEP GMBH (DE) | 2008-09-25 | — | — | US | claimed |
| CN-101273136-A | Process for enantioselective enzymatic reduction of keto compounds | IEP GMBH (DE) | 2008-09-24 | — | — | CN | claimed |
| US-20250275560-A1 | PROCESS OF MAKING GINGEROL COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | FIRMENICH SA (CH) | 2025-09-04 | — | — | US | disclosed |
| EP-4307919-A2 | PROCESS OF MAKING GINGEROL COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | Firmenich SA (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-102341501-B | Method for stereoselectively and enzymatically reducing keto compounds | IEP GMBH | 2015-07-08 | — | — | CN | disclosed |
| US-9045780-B2 | Process for the stereoselective enzymatic reduction of keto compounds | IEP GMBH (DE) | 2015-06-02 | — | — | US | disclosed |
| US-9040265-B2 | Oxidoreductases for the stereoselective reduction of keto compounds | IEP GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-8951998-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2143727-B1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20140371148-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | ASTRAZENECA PHARMACEUTICALS LP | 2014-12-18 | — | — | US | disclosed |
| US-4483850-A | HYPOTENSIVE AGENTS | MERCK & CO., INC. (US) | 1984-11-20 | — | — | US | disclosed |
| US-4477464-A | Hetero-benzazepine derivatives and their pharmaceutical use | CIBA-GEIGY CORPORATION (US) | 1984-10-16 | — | — | US | disclosed |
| EP-0120728-A1 | Thiazine and thiazepine containing compounds | E.R. Squibb & Sons, Inc. (US) | 1984-10-03 | — | — | EP | disclosed |
| US-4460579-A | HYPOTENSIVE AGENTS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1984-07-17 | — | — | US | disclosed |
| EP-0080822-A1 | Anti-hypertensive prolinol-based peptides | BEECHAM GROUP PLC (GB) | 1983-06-08 | — | — | EP | disclosed |
| EP-0058918-A1 | Aza analogs of aminoacid derivatives as antihypertensives | MERCK & CO. INC. (US) | 1982-09-01 | — | — | EP | disclosed |
| EP-0054862-A1 | Substituted dipeptides, processes for their preparation and pharmaceutical compositions containing them and their use in the inhibition of enkephalinase | SCHERING CORPORATION (US) | 1982-06-30 | — | — | EP | disclosed |
| EP-0049506-A1 | N-carboxyalkyl dipeptides, a process for preparing and a pharmaceutical composition comprising the same | MERCK & CO. INC. (US) | 1982-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275560-A1 | PROCESS OF MAKING GINGEROL COMPOUNDS AND THEIR USE AS FLAVOR MODIFIERS | GMPS, UMPS, IMPDH1 | GABBR2 1715/4885GABBR1 2077/4885LMNA 2395/4885 |
| US-20140371148-A1 | PEPTIDE-PEPTIDASE INHIBITOR CONJUGATES AND METHODS OF USING SAME | DNPEP, PEPD, VIP | GABBR2 2957/4885GABBR1 3172/4885LMNA 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.